NEW YORK–(BUSINESS WIRE)–New Mountain Capital announced that it has reached a definitive agreement with Aurobindo Pharma to acquire Natrol and combine it with Jarrow Formulas, another New Mountain Capital portfolio company. The transaction is expected to close by January 2021 subject to customary closing conditions and regulatory approvals.
Headquartered in Los Angeles, CA, Natrol is a leading vitamins, minerals and supplements brand focused on vital human health areas including sleep, mood & stress, brain health, beauty and immunity. Founded in 1980, Natrol has grown to be the #1 natural sleep brand. Natrol is trusted by consumers across the globe and has an established reputation for scientific efficacy, high quality and innovation.
“Throughout its history, Natrol has stood for the highest quality products designed to drive positive outcomes and enhance quality of life for its users,” said Andre Moura, Managing Director at New Mountain Capital. “We thank Aurobindo for their stewardship of Natrol over the last six years, and we look forward to working closely with the management teams at Natrol and Jarrow Formulas to build upon Natrol’s strong momentum and drive continued growth and market-leading innovation.”
“Aurobindo is committed to evaluating and concluding strategic options towards focused portfolio enhancement with the ultimate objective of enhancing stakeholder values. We are pleased to enter into an agreement to sell the Natrol business to an outstanding private equity player, who can focus additional resources to grow Natrol, its products and brands further. On behalf of the Aurobindo Group, my heartful thanks to all stakeholders including employees, who have supported in acquiring and bringing Natrol to a growth path in the past 6 years,” said Mr. N. Govindarajan, Managing Director, Aurobindo Pharma Limited. “Proceeds from Natrol’s divestiture will be used to reduce debt and other new strategic initiatives.”
Simpson Thacher & Bartlett LLP acted as legal counsel to New Mountain Capital. Jefferies served as the sole financial advisor to Aurobindo, and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo.
About New Mountain Capital:
New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, public equity, and credit funds with over $28 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit www.newmountaincapital.com.
About Aurobindo Pharma Limited:
Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.
This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch , implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.
For further information, please contact:
New Mountain Capital
Email: [email protected]
Aurobindo Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: [email protected]